|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2006-7-5
|
|
pubmed:abstractText |
Because raised matrix metalloprotease (MMP) levels are associated with glioma invasion and angiogenesis, we tested the efficacy of marimastat (MT) an orally active drug that can reduce MMP levels, in patients with gliomas.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0167-594X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
78
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
295-302
|
|
pubmed:meshHeading |
pubmed-meshheading:16636750-Adult,
pubmed-meshheading:16636750-Aged,
pubmed-meshheading:16636750-Brain Neoplasms,
pubmed-meshheading:16636750-Combined Modality Therapy,
pubmed-meshheading:16636750-Double-Blind Method,
pubmed-meshheading:16636750-Enzyme Inhibitors,
pubmed-meshheading:16636750-Female,
pubmed-meshheading:16636750-Glioblastoma,
pubmed-meshheading:16636750-Gliosarcoma,
pubmed-meshheading:16636750-Humans,
pubmed-meshheading:16636750-Hydroxamic Acids,
pubmed-meshheading:16636750-Male,
pubmed-meshheading:16636750-Matrix Metalloproteinases,
pubmed-meshheading:16636750-Middle Aged,
pubmed-meshheading:16636750-Musculoskeletal Diseases,
pubmed-meshheading:16636750-Quality of Life,
pubmed-meshheading:16636750-Survival Analysis,
pubmed-meshheading:16636750-Treatment Failure
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation.
|
|
pubmed:affiliation |
Department of Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. vlevin@mdanderson.org
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Multicenter Study
|
